Dr Lawrence Lewis Reynolds, MD | |
252 Seldovia St, Seldovia, AK 99663-0210 | |
(907) 234-7825 | |
(907) 234-7825 |
Full Name | Dr Lawrence Lewis Reynolds |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 252 Seldovia St, Seldovia, Alaska |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1417020348 | NPI | - | NPPES |
MD1164 | Medicaid | AK | |
0200641039 | Other | CLIA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 1164 (Alaska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Lawrence Lewis Reynolds, MD Drawer J, 252 Seldovia St, Seldovia, AK 99663-0210 Ph: (907) 234-7825 | Dr Lawrence Lewis Reynolds, MD 252 Seldovia St, Seldovia, AK 99663-0210 Ph: (907) 234-7825 |
News Archive
"Southeast Asia's 600 million people are facing a raft of new health challenges as the disaster-prone region undergoes some of the world's fastest social change," according to a series of papers and commentary pieces, published Tuesday in the Lancet, Agence France-Presse reports (O'Brien, 1/25).
Researchers have shown that point mutations mis-spellings in a single letter of genetic code that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalised medicine in which every patient could have their tumour screened, specific mutations identified, and the appropriate drug chosen to target the mutation and halt the growth of their cancer.
The National Fragile X Foundation has awarded a translational research seed grant of $100,000 to Dr. Randi J. Hagerman at the UC Davis M.I.N.D. Institute in California for a study of minocycline in the treatment of children with fragile X syndrome (FXS). Hagerman is an internationally recognized clinician and clinical researcher on FXS, the most common cause of inherited mental impairment.
Novartis today announced a first-of-its-kind collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes.
› Verified 6 days ago